Integrity Alliance LLC. Acquires New Holdings in Zevra Therapeutics, Inc. $ZVRA

Integrity Alliance LLC. acquired a new position in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) in the third quarter, HoldingsChannel reports. The institutional investor acquired 938,167 shares of the company’s stock, valued at approximately $10,292,000.

A number of other institutional investors also recently made changes to their positions in ZVRA. AIGH Capital Management LLC acquired a new position in shares of Zevra Therapeutics in the first quarter valued at approximately $11,184,000. Dimensional Fund Advisors LP increased its stake in shares of Zevra Therapeutics by 259.2% during the first quarter. Dimensional Fund Advisors LP now owns 554,802 shares of the company’s stock worth $5,168,000 after purchasing an additional 400,336 shares during the period. Hennion & Walsh Asset Management Inc. lifted its holdings in Zevra Therapeutics by 116.6% during the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 383,706 shares of the company’s stock worth $5,502,000 after purchasing an additional 206,543 shares during the last quarter. Mystic Asset Management Inc. lifted its holdings in Zevra Therapeutics by 0.9% during the 3rd quarter. Mystic Asset Management Inc. now owns 355,380 shares of the company’s stock worth $3,899,000 after purchasing an additional 3,270 shares during the last quarter. Finally, Janney Montgomery Scott LLC boosted its stake in Zevra Therapeutics by 16.7% in the 1st quarter. Janney Montgomery Scott LLC now owns 236,834 shares of the company’s stock valued at $2,207,000 after purchasing an additional 33,951 shares during the period. Institutional investors own 35.03% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have commented on ZVRA shares. Citigroup reaffirmed an “outperform” rating on shares of Zevra Therapeutics in a report on Thursday, August 6th. HC Wainwright reissued a “buy” rating and issued a $26.00 target price on shares of Zevra Therapeutics in a research report on Thursday, August 20th. Citizens Jmp upped their price target on shares of Zevra Therapeutics from $25.00 to $28.00 and gave the company a “market outperform” rating in a research note on Thursday, August 6th. Wall Street Zen raised shares of Zevra Therapeutics from a “hold” rating to a “buy” rating in a research report on Sunday, July 12th. Finally, Canaccord Genuity Group dropped their price objective on shares of Zevra Therapeutics from $29.00 to $20.00 and set a “buy” rating for the company in a research note on Monday, July 27th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $27.14.

Zevra Therapeutics Trading Up 1.6%

Shares of NASDAQ:ZVRA opened at $10.26 on Wednesday. The firm has a 50 day moving average of $11.11 and a 200-day moving average of $10.75. The stock has a market capitalization of $609.24 million, a PE ratio of 6.39 and a beta of 1.01. Zevra Therapeutics, Inc. has a 12 month low of $8.01 and a 12 month high of $15.03.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its quarterly earnings results on Tuesday, November 3rd. The company reported $0.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.16 by $0.10. The business had revenue of $37.76 million for the quarter, compared to analyst estimates of $37.08 million. Zevra Therapeutics had a net margin of 42.82% and a return on equity of 54.54%. On average, research analysts predict that Zevra Therapeutics, Inc. will post 0.72 EPS for the current fiscal year.

Insider Activity at Zevra Therapeutics

In other Zevra Therapeutics news, CEO Neil McFarlane sold 20,000 shares of the company’s stock in a transaction on Monday, October 12th. The stock was sold at an average price of $11.25, for a total transaction of $225,000.00. Following the completion of the sale, the chief executive officer directly owned 417,225 shares in the company, valued at $4,693,781.25. This represents a 4.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Corey Watton sold 12,300 shares of the firm’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $11.25, for a total value of $138,375.00. Following the completion of the sale, the director directly owned 1,800 shares in the company, valued at approximately $20,250. This represents a 87.23% decrease in their position. The SEC filing for this sale provides additional information. 3.70% of the stock is owned by insiders.

About Zevra Therapeutics

Zevra Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases and other conditions with significant unmet medical needs. The company combines traditional drug development with data science and patient-focused research to advance therapies for diseases that may have limited treatment options.

Zevra’s lead commercial product is MIPLYFFA (arimoclomol), which is approved in the United States for the treatment of neurological manifestations of Niemann-Pick disease type C in adults and children aged 2 years and older, in combination with miglustat.